Cargando…

Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer

PURPOSE: Metastasis-directed therapy (MDT) is increasingly used in castration-sensitive oligometastatic prostate cancer because it prolongs progression-free survival (PFS) and androgen deprivation free survival. Here we describe patterns of recurrence and identify modes of progression after MDT usin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deek, Matthew P., Taparra, Kekoa, Dao, Dyda, Chan, Luanna, Phillips, Ryan, Gao, Robert W., Kwon, Eugene D., Deville, Curtiland, Song, Daniel Y., Greco, Stephen, Carducci, Michael A., Eisenberger, Mario, DeWeese, Theodore L., Denmeade, Samuel, Pienta, Kenneth, Paller, Channing J., Antonarakis, Emmanuel S., Olivier, Kenneth R., Park, Sean S., Stish, Bradley J., Tran, Phuoc T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856169/ https://www.ncbi.nlm.nih.gov/pubmed/32798608 http://dx.doi.org/10.1016/j.ijrobp.2020.08.030

Ejemplares similares

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience
por: Deek, Matthew P., et al.
Publicado: (2019)

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
por: Radwan, Noura, et al.
Publicado: (2017)

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
por: Phillips, Ryan, et al.
Publicado: (2020)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
por: Hasan, Hamza, et al.
Publicado: (2020)

Native Hawaiian and Other Pacific Islander Representation Among US Allopathic Medical Schools, Residency Programs, and Faculty Physicians
por: Taparra, Kekoa, et al.
Publicado: (2021)

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
por: Deek, Matthew P., et al.
Publicado: (2021)

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
por: Kapoor, Roche, et al.
Publicado: (2019)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
por: Deek, Matthew P., et al.
Publicado: (2022)

The biology and treatment of oligometastatic cancer
por: Reyes, Diane K., et al.
Publicado: (2015)

CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer
por: Sheikhbahaei, Sara, et al.
Publicado: (2020)

Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes
por: Taparra, Kekoa, et al.
Publicado: (2016)

Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion
por: Tran, Phuoc T., et al.
Publicado: (2017)

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer
por: Torquato, Samantha, et al.
Publicado: (2019)

The Game Continues: Seeking Clarity in the Radiation Oncology Match
por: Ebner, Daniel K., et al.
Publicado: (2020)

Oligometastatic Prostate Cancer to the Navicular Bone: Case Report
por: Reyes, Diane K., et al.
Publicado: (2015)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Cancer Disparities among Pacific Islanders: A Review of Sociocultural Determinants of Health in the Micronesian Region
por: Pineda, Eric, et al.
Publicado: (2023)

End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
por: Narang, Amol K., et al.
Publicado: (2017)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With Cancer
por: Taparra, Kekoa, et al.
Publicado: (2022)

Uptake of [(18)F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies
por: Rowe, Steven P., et al.
Publicado: (2015)

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
por: Katano, Atsuto, et al.
Publicado: (2021)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer
por: Reyes, D. K., et al.
Publicado: (2020)

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted (18)F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern
por: Yin, Yafu, et al.
Publicado: (2019)

Online Prostate-Specific Membrane Antigen and Positron Emission Tomography–Guided Radiation Therapy for Oligometastatic Prostate Cancer
por: Hrinivich, William T., et al.
Publicado: (2019)

A Review of Pomegranate in Prostate Cancer
por: Paller, Channing J., et al.
Publicado: (2017)

Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer
por: Bazyar, Soha, et al.
Publicado: (2023)

Racial and Ethnic Disparities in Rates of Invasive Second Breast Cancer Among Women With Ductal Carcinoma In Situ in Hawaiʻi
por: Taparra, Kekoa, et al.
Publicado: (2021)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

The Path Forward Toward Health Equity in Radiation Oncology in a Post-2020 Era
por: Deville, Curtiland
Publicado: (2023)

Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020)

Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
por: Zhang, Vivian, et al.
Publicado: (2023)

Detection fidelity of AR mutations in plasma derived cell-free DNA
por: Goldstein, Alexa, et al.
Publicado: (2017)

Usefulness of robot‐assisted radical prostatectomy in a patient with oligometastatic castration‐resistant prostate cancer
por: Koie, Takuya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_prsa2e7deciocr8eutiein1og7